Helix Twelve Pharmaceuticals Appoints Fred R. Seddiqui as Chief Executive Officer
PALO ALTO, Calif., Sept. 27, 2016 /PRNewswire/ -- Helix Twelve Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development of next-generation precision therapeutics, today announced that its Board of Directors has appointed Fred R. Seddiqui as Chief Executive Officer, effective immediately.
Seddiqui brings more than 30 years of industry experience to Helix Twelve, where he has held various global executive positions in medical device and biotechnology companies. Over the past three years, he has served as an executive advisor to Helix Twelve and a member of their Board of Directors.
"We are excited to welcome Fred to the role of CEO. He is a strong, visionary leader with deep global life science experience, as well as proven executional expertise and commitment," said Dr. Masato Tanabe, founder, and chairman of Helix Twelve Pharmaceuticals, Inc. "We believe his appointment will provide new dynamism to Helix Twelve's development program in leveraging our novel molecular targeted therapies toward partnership and commercialization."
"Joining Helix Twelve as CEO at this pivotal time in its lifecycle is a great privilege," said Seddiqui. "With the company's deep product pipeline, and a well-honed team they have successfully forged a rapid commercialization path for their lead investigational compounds, primarily in cancer treatment. Helix Twelve is positioned to be a highly successful company with an arsenal of next-generation drugs that have the potential to benefit the lives of many patients. I am proud and motivated to join a team of such well-respected team of scientists, and execute on the mission to advance the frontier of medicine."
About Helix Twelve
Helix Twelve Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the development of precision therapeutics, with a drug pipeline that includes product candidates in later-stage clinical development. Diseases targeted by Helix Twelve's drug development pipeline include women's health, heart disease, and cancer.
Helix Twelve was recently granted exclusive rights from SRI International to develop and commercialize the company's lead product candidate, HLX-801, a next-generation oral selective estrogen receptor modulator (SERM). This late stage investigational compound has already shown very promising results from Phase II studies in the treatment of breast cancer.
To learn more about Helix Twelve please visit www.helixtwelve.net.
Media Contact:
Kate McNemar
(650) 382-2069
[email protected]
SOURCE Helix Twelve Pharmaceuticals, Inc.
Share this article